Alivexis, Inc. (formerly Modulus Discovery, Inc.) is thrilled to announce the successful raise of US$6,000,000 in our latest funding round—a strong vote of confidence in our mission and innovative strategy in the drug discovery landscape. With operational foundations in both Japan and the US, Alivexis stands at the forefront of technology-driven drug discovery, merging state-of-the-art platforms with an extensive understanding of disease biology. This infusion of capital marks a pivotal moment in our journey as we work to redefine the future of therapeutic innovation.
The new funding will be strategically allocated to accelerate the development of our unique portfolio of small molecule drugs, further strengthening our research and development collaborations. It will support the expansion of our laboratory capabilities and enhance our global R&D operations, ensuring that our initiatives remain at the cutting edge of scientific discovery. As we harness advanced computational tools and streamline innovative processes, our commitment is to address unmet medical needs with dynamic, personalized treatment solutions.
Moreover, this investment will empower us to broaden our pipeline and rapidly iterate on promising research collaborations, allowing our global teams to cultivate breakthroughs that can transform patient care. Alivexis’ dual presence in Japan and the US uniquely positions us to integrate diverse scientific approaches and leverage international expertise. We are excited to channel these funds into high-impact projects that drive therapeutic advancements and fuel our continuous pursuit of excellence in drug discovery. This milestone not only reinforces our leadership in the field but also sets the stage for a future where innovative science and groundbreaking technology converge to create lasting benefits for patients worldwide.
